Evidence map›Paper›PMID 41709122›Full record

ArticleChemical biology & drug design2026

New Non-Saccharide Heparin Mimetics as Inhibitors of Cathepsin G.

Daniel K Afosah, Madhusoodanan Mottamal, Srabani Kar, Emily Lauren Schenk Smith, Alexandra C Selico-Dunn, Syed A Ahmed, Rami A Al-Horani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical biology & drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel K AfosahDepartment of Chemistry, College of Science, University of North Texas, Denton, Texas, USA.
Madhusoodanan MottamalDepartment of Chemistry, College of Arts and Science, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Srabani KarDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Emily Lauren Schenk SmithDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Alexandra C Selico-DunnDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Syed A AhmedDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, USA.
Rami A Al-HoraniDivision of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana, USA.ORCID https://orcid.org/0000-0001-9146-2662

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Sara Abdul Sattar Al-Dahir · 2019 to 2026
$41.9M
Synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesisR00HL161423 · NHLBI · UNIVERSITY OF NORTH TEXAS · PI Daniel Kwame Afosah · 2024 to 2026
$683k
Inhibitors of Human Factor XIIIa as New AnticoagulantsR16GM149412 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI Rami A Al-Horani · 2023 to 2026
$599k
NHLBI NIH HHS R00 HL161423NHLBI NIH HHS R00HL161423NIGMS NIH HHS R16 GM149412NIGMS NIH HHS R16GM149412NIMHD NIH HHS U54 MD007595NIMHD NIH HHS U54MD007595
6 · The paper itself

Abstract

Cathepsin G (CatG), a neutrophil serine protease, plays several roles in host defense, inflammation, and vascular pathology. Selective inhibition of CatG is therefore a compelling therapeutic strategy, yet existing inhibitors such as sulfated saccharides are limited by structural heterogeneity, instability, and bleeding risk. In this study, sulfonated non-saccharide heparin mimetics were explored as a new class of CatG inhibitors with improved stability and drug-like properties. A focused library of derivatives was screened, and several candidates demonstrated potent inhibition, with the most active compound (inhibitor 7) achieving complete CatG inhibition at nanomolar concentrations (IC

Indexed as

Cathepsin GHeparinBinding SitesHumansMolecular Docking SimulationCathepsin GHeparinallosteric inhibitorscathepsin Gheparin mimeticsinflammationsulfonatevascular diseases

Identifiers

PMID41709122
PMCPMC13036795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.